Triple Therapy With Tegoprazan in H. Pylori Positive Patients

• Status: Completed
• Trial end date: 2019-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The current study is designed to demonstrate the non-inferiority of tegoprazan triple therapy (tegoprazan, amoxicillin, and clarithromycin; hereinafter TAC) to lansoprazole triple therapy (lansoprazole, amoxicillin, and clarithromycin; hereinafter LAC) in terms of H. pylori eradication rate and to evaluate the safety of tegoprazan after oral administration of the therapy for 7 days, twice daily in H. pylori positive patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CJ HealthCare Corporation; HK inno.N Corporation
• Treatments: Amoxicillin; Clarithromycin; Dexlansoprazole; Lansoprazole

Criteria

Inclusion Criteria:

• H. pylori positive based on the screening test

• Peptic ulcer disease

Exclusion Criteria:

• Prior treatment for H. pylori eradication

• Prior use of proton pump inhibitors (PPIs), H2 receptor blockers, at a full dosage within 14 days

• Prior use of H. pylori eradication effective antibiotics, bismuth within 14 days